|
here are some of the best articles on this...6 & 17 are especially good
Johnson PH, Esteva FJ. Related Articles, Links
The use of HER2 modulation in the adjuvant setting.
Curr Oncol Rep. 2007 Jan;9(1):9-16.
PMID: 17164042 [PubMed - in process]
6: Nahta R, Esteva FJ. Related Articles, Links
HER2 therapy: Molecular mechanisms of trastuzumab resistance.
Breast Cancer Res. 2006 Nov 6;8(6):215 [Epub ahead of print]
PMID: 17096862 [PubMed - as supplied by publisher]
10: Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Related Articles, Links
Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Oncologist. 2006 Sep;11(8):857-67. Review.
PMID: 16951389 [PubMed - indexed for MEDLINE]
14: Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Related Articles, Links
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.
PMID: 16683005 [PubMed - indexed for MEDLINE]
15: Pusztai L, Esteva FJ. Related Articles, Links
Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.
Cancer Invest. 2006 Mar;24(2):187-91. Review.
PMID: 16619408 [PubMed - indexed for MEDLINE]
17: Nahta R, Esteva FJ. Related Articles, Links
Herceptin: mechanisms of action and resistance.
Cancer Lett. 2006 Feb 8;232(2):123-38. Review.
PMID: 16458110 [PubMed - indexed for MEDLINE]
19: Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Related Articles, Links
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Cancer Res. 2005 Dec 1;65(23):11118-28.
PMID: 16322262 [PubMed - indexed for MEDLINE]
|